High Court Declines Review Of Ruling In Securities Suit Against Drug Maker

WASHINGTON, D.C. - The U.S. Supreme Court on Oct. 7 declined to review a First Circuit U.S. Court of Appeals ruling affirming in part and reversing in part a federal court's ruling that shareholders in a securities class action lawsuit failed to properly plead their claims in arguing that a pharmaceutical company and others misrepresented a number of facts regarding an iron-replacement drug the company was developing (AMAG Pharmaceuticals Inc., et al. v. Silverstrand Investments, et al., No. 12-1457, U.S. Sup.).

Access this news story on lexis.com®